At this year’s conference, pharmaphorum editor-in-chief Jonah Comstock caught up with Catherine Owen Adams, the CEO of Acadia ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

In his first speech since being appointed Health and Human Services Secretary, Robert F Kennedy Jr pledged to investigate the ...

The text of the bill is vanishingly short and does not give any indication of the drugs that might be prescribed by AIs or ...

Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan ...

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...